期刊文献+

罗格列酮对2型糖尿病患者骨密度及骨代谢指标的影响 被引量:5

Effects of rosiglitazone on bone mineral density and bone metabolism indexes in patients with type 2 diabetes
原文传递
导出
摘要 目的:探讨罗格列酮对2型糖尿病患者骨密度(BMD)及骨代谢指标的影响。方法:172例2型糖尿病患者随机分为对照组和罗格列酮治疗组,每组86例。罗格列酮治疗组给予罗格列酮4mg.d-1,治疗3个月。分别于治疗前后,测定2组的BMD、血清骨碱性磷酸酶(BAP)、骨钙素(OC)和护骨素(OPG)等指标的变化。结果:治疗3个月后,罗格列酮治疗组髋部及腰椎BMD显著下降,血清BAP、OC和OPG也明显降低;而对照组的BMD、血清BAP、OC和OPG在治疗前后无明显变化。结论:罗格列酮可能通过降低血清BAP、OC和OPG水平,使2型糖尿病患者的BMD降低,从而具有潜在的致骨质疏松的作用。 OBJECTIVE To investigate the effects of rosiglitazone on bone mineral density and bone metabolism indexes in patients with type 2 diabetes. METHODS 172 patients with type 2 diabetes were randomly divided into control group and rosiglitazone treated group (86 patients in each group). The patients in rosiglitazone treated group were treated with rosiglitazone (4 mg·d ^-1 ) for 3 months. Then bone mineral density, serum bone-specific alkaline phosphatase, osteocalcin and osteoprotegerin were detected in the two groups before and after treatment. RESULTS After treatment for 3 months, decreased levels of hip and lumbar spine BMD, serum bone-specie alkaline phosphatase, osteoealein and osteoprotegerin were found in rosiglitazone treating group. However. there were no significant differences in the level of bone mineral density, serum bone-specie alkaline phosphatase, osteocalcin and osteoprotegerin between before and after treatment among the control group. CONCLUSION Rosiglitazone decreases bone mineral density among patients with type 2 diabetes via reducing the levels of serum bone-specific alkaline phosphatase, osteocalcin and osteoprotegerin,then may leads to osteoporosis.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2011年第7期577-579,共3页 Chinese Journal of Hospital Pharmacy
关键词 罗格列酮 2型糖尿病 骨密度 碱性磷酸酶 骨钙素 护骨素 rosiglitazone type 2 diabetes bone mineral density bonespecific alkaline phosphalase osteocalcin osteoprotegerin
  • 相关文献

参考文献2

  • 1Berberoglu Z, Yazici AC, Demirag NG. Effects of rosiglita-zone on bone mineral density and remodelling parameters inPostmenopausal diabetic women: a 2 year follow up study[J].Clin Endocrinol (Oxf), 2010, 73(3) :305-312. 被引量:1
  • 2Douglas IJ, Evans SJ, Pocock S, et al. The risk of fractures associated with thiazolidinediones: a selfcontrolled case-series study[J].PLoS Med, 2009, 6(9):e1000154. 被引量:1

同被引文献61

引证文献5

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部